These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3694431)

  • 1. A study on furosemide disposition in man.
    Zhu JB; Koizumi T
    J Pharmacobiodyn; 1987 Aug; 10(8):370-6. PubMed ID: 3694431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diuretic effect and disposition of furosemide in cystic fibrosis.
    Prandota J; Smith IJ; Hilman BC; Wilson JT
    Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
    Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
    Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based meta-analysis of furosemide pharmacokinetics.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2014 Mar; 35(2):119-33. PubMed ID: 24151207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of furosemide in patients with congestive heart failure.
    Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K
    Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.
    Kim SH; Choi YM; Lee MG
    J Pharmacokinet Biopharm; 1993 Feb; 21(1):1-17. PubMed ID: 8410679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide disposition in patients on CAPD.
    Martin U; Winney RJ; Prescott LF
    Eur J Clin Pharmacol; 1995; 48(5):385-90. PubMed ID: 8641327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.
    Alván G; Beermann B; Hjelte L; Lind M; Lindholm A; Strandvik B
    Clin Pharmacol Ther; 1988 Oct; 44(4):436-41. PubMed ID: 3168395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
    Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
    Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diuretic effect of furosemide in relation to its disposition in man.
    Zhu JB; Koizumi T
    J Pharmacobiodyn; 1987 Aug; 10(8):377-83. PubMed ID: 3694432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers.
    van Meyel JJ; Smits P; Russel FG; Gerlag PG; Tan Y; Gribnau FW
    Clin Pharmacol Ther; 1992 Apr; 51(4):440-4. PubMed ID: 1563213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
    Vree TB; van der Ven AJ
    J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal first-pass effect of furosemide in rats.
    Kim EJ; Han KS; Lee MG
    J Pharm Pharmacol; 2000 Nov; 52(11):1337-43. PubMed ID: 11186241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and absolute bioavailability of furosemide in healthy males.
    Waller ES; Hamilton SF; Massarella JW; Sharanevych MA; Smith RV; Yakatan GJ; Doluisio JT
    J Pharm Sci; 1982 Oct; 71(10):1105-8. PubMed ID: 7143205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.
    Rakhit A; Kochak GM; Tipnis V; Hurley ME
    Clin Pharmacol Ther; 1987 May; 41(5):580-6. PubMed ID: 3032491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.